Archive | August, 2021

Hot Longevity Mandates: Multinational Venture Firm

3 Aug

The firm is a venture capital fund founded in 1996 with offices in the US, China, and Japan. The firm has over $4.2B assets under management and has invested in over 400 companies. In 2019, the firm closed Fund IX at $780M, its largest fund to date. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm aims to make at least 1-2 USA-based and 1 China-based investments per year.

The firm is mainly interested in digital health opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm include a Google Glass-powered remote scribe platform that improves the workflow of physicians, an AI engine that matches cancer patients with clinical trials, a wearable health tracker for healthy lifestyle management, etc. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: Taiwan-Based Family Office

3 Aug

The family office investment fund is based in Taiwan. The fund focuses on healthcare, with investments including healthcare services as well as novel health technologies. The firm focuses on China, Taiwan and the US, and usually invests about $1 million per deal, but as the firm is a multi-stage investor, larger allocations are possible.

The fund is interested in medical devices, diagnostics and digital health, in addition to healthcare services. The firm is open to any indication area but has a particular interest in cardiology. The fund can make early stage investments but requires that the company at least have a working prototype/pilot product.

The fund primarily invests in companies that have operations in Asia but will also consider US-based companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: US-Based Venture Firm

3 Aug

The firm is a venture capital firm that was founded in 2019 and is headquartered in Western US. The firm is seeking opportunities across all sectors of life sciences with a focus on biotechnologies, digital health, and infosec. The firm will engage in seed to series B rounds, but mostly looking to invest in series A. A typical allocation can range from 4 – 8 million USD. The firm will invest in companies that are based/headquartered in the US. The firm prefers to lead the investment round and will seek board seats when leading.

The firm is interested in novel technologies that address significant unmet needs in life sciences. The firm is most focused on biotechnologies and digital health but is open to considering all sectors in life sciences. Within the therapeutics sector, the firm is most interested in companies with a diversified pipeline in pre-clinical and clinical trial stages. The firm will consider opportunities in any indication, but has particular interest in oncology, immunology, and neurology. Within the digital health sector, the firm is interested in companies focused on value-based care models and technologies that incorporate machine learning and AI. The firm is also opened to considering medical devices and diagnostics companies of all stages of development. The firm is opportunistic in terms of subsectors and indications in these sectors.

The firm has no strict company or management team requirements, but prefers to work with companies led by founders with strong scientific and technical expertise. The firm does look to take an active role in helping the company to grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Improving Diabetes Management with AI-Driven Glucose Sensors – Interview with Marc Ripper, PhD, CEO of Alertgy

2 Aug

By Erika Wu, Business Development Representative, LSN

Is the future of diabetes management here? Learn about what Dr. Marc Rippen and his team at Alertgy are achieving with their patented technology and artificial intelligence (AI) to provide on-demand blood glucose readings. You can also see Alertgy at the Innovator’s Pitch Challenge during the digital RESI Partnering Week, September 13-17. Join RESI AI (September 16-17) for dynamic panels, as well as opportunities to pitch to a live panel of investors. Learn more about how you can get involved and tell your story at Innovator’s Pitch Challenge!

Newer Entries →